Participants 30 115 4
patients with advanced prostate cancer treated by castration plus anandron or placebo
Participants 627 894 5
399 out of 457 patients recruited in this study were divided in a good or poor prognostic group depending on the presence of two or more poor prognostic factors, these were pain requiring treatment, >5 bone metastases, hydronephrosis, and alkaline phosphatase >2 ULN.
Participants 1235 1275 3
patients with metastatic prostate cancer
